Adaptive Biotechnologies Corp (ADPT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Adaptive Biotechnologies Corp (ADPT) has a cash flow conversion efficiency ratio of -0.035x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.13 Million) by net assets ($204.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ADPT net asset quality score to measure how much of total assets are equity-financed.
Adaptive Biotechnologies Corp - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Adaptive Biotechnologies Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ADPT cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Adaptive Biotechnologies Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adaptive Biotechnologies Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Advanced Technology & Materials Co Ltd
SHE:000969
|
0.044x |
|
KANSAI PAINT SPON.ADR/1/2
F:KAP0
|
N/A |
|
Whirlpool Corporation
NYSE:WHR
|
-0.219x |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
-0.014x |
|
Hub Group Inc
NASDAQ:HUBG
|
0.016x |
|
Haemonetics Corporation
NYSE:HAE
|
0.089x |
|
Zhuhai CosMX Battery Co Ltd
SHG:688772
|
0.111x |
|
Dunelm Group plc
F:DFQ
|
0.411x |
Annual Cash Flow Conversion Efficiency for Adaptive Biotechnologies Corp (2017–2024)
The table below shows the annual cash flow conversion efficiency of Adaptive Biotechnologies Corp from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see Adaptive Biotechnologies Corp (ADPT) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $202.49 Million | $-95.21 Million | -0.470x | +7.27% |
| 2023-12-31 | $308.28 Million | $-156.32 Million | -0.507x | -27.94% |
| 2022-12-31 | $464.10 Million | $-183.94 Million | -0.396x | -24.24% |
| 2021-12-31 | $604.10 Million | $-192.73 Million | -0.319x | -58.42% |
| 2020-12-31 | $743.27 Million | $-149.68 Million | -0.201x | -155.99% |
| 2019-12-31 | $571.04 Million | $205.40 Million | 0.360x | +187.81% |
| 2018-12-31 | $-258.11 Million | $-32.26 Million | 0.125x | -19.47% |
| 2017-12-31 | $-224.62 Million | $-34.86 Million | 0.155x | -- |
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diag… Read more